Omnicare Receives Average Rating of “Buy” from Brokerages (NYSE:OCR)
Shares of Omnicare (NYSE:OCR) have been given a consensus recommendation of “Buy” by the seven analysts that are presently covering the company, Stock Ratings News reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $68.17.
Omnicare (NYSE:OCR) opened at 62.66 on Wednesday. Omnicare has a 1-year low of $52.26 and a 1-year high of $67.49. The stock’s 50-day moving average is $65.05 and its 200-day moving average is $61.93. The company’s market cap is $6.131 billion.
Omnicare (NYSE:OCR) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.90 by $0.01. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter in the prior year, the company posted $0.90 earnings per share. The company’s quarterly revenue was up 7.2% on a year-over-year basis. On average, analysts predict that Omnicare will post $3.69 earnings per share for the current fiscal year.
OCR has been the subject of a number of recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Omnicare in a research note on Thursday, July 24th. They now have a $73.00 price target on the stock, up previously from $68.00. Separately, analysts at Barclays initiated coverage on shares of Omnicare in a research note on Thursday, July 17th. They set an “equal weight” rating on the stock. Finally, analysts at Bank of America reiterated a “buy” rating on shares of Omnicare in a research note on Friday, June 20th. They now have a $73.00 price target on the stock, up previously from $69.00.
Omnicare, Inc (NYSE:OCR) is a healthcare services company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.